---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021615"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:56:09.579148+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech discontinues Tissue Health Plus, reallocates resources to surgical business

## Summary
- Completed evaluation of strategic alternatives for THP; ceased development in late September and will discontinue operations.
- THP segment will be classified as discontinued operations; wind-down expected through end of 2025.
- Total cash investment in THP expected $5.5M to $6.5M in H2 2025; no material cash expenses after year-end.
- Management believes surgical business has greatest potential for sustainable long-term growth and value.
- Further details to be discussed on Q3 2025 earnings call scheduled for November 12, 2025.

## SEC filing metadata
- accession: 0001493152-25-021615
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315225021615/0001493152-25-021615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315225021615/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021615
- JSON: https://secwatch.observer/filing/0001493152-25-021615.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.